Health Economics›Acute myeloid leukemia›First-line induction therapy older or "unfit" patients

First-line induction therapy older or "unfit" patients

Acute myeloid leukemia · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
LoDAC and Venetoclax Variant #01	—	R 283 869	28d	—	8.4 mo	3	R 431 269 PFS proxy	1
Azacitidine and Venetoclax Variant #01	—	R 220 316	28d	—	14.1 mo	3	R 376 652 PFS proxy	3
Decitabine and Venetoclax Variant #01	—	R 113 712	28d	—	—	~2	~R 227 424 indirect	—
Azacitidine and Gemtuzumab ozogamicin Variant #01	—	R 72 311	8d	—	—	~1	~R 72 311 indirect	—
FLAG Variant #01	—	R 47 479	—	—	~6.7 mo	~2	~R 94 958 PFS proxy · indirect	1
Decitabine monotherapy Variant #01	—	R 32 080	42d	—	7.7 mo	2	R 64 160 PFS proxy	2
Azacitidine monotherapy Variant #01	—	R 29 332	28d	—	9.8 mo	6	R 175 992 PFS proxy	7
Gemtuzumab ozogamicin monotherapy Variant #04	—	R 28 653	8d	—	4.9 mo	8	R 229 221 PFS proxy	1
Cytarabine and Etoposide (CYVE) Variant #06	NPM1	R 4 351	—	—	9.2 mo	2	R 8 701 PFS proxy	—
Temozolomide monotherapy Variant #02	—	R 3 434	14d	~4.0 mo	~16.3 mo	~27	~R 92 712 PFS proxy · indirect	10
Low-dose Cytarabine monotherapy (LoDAC) Variant #01	—	R 1 249	28d	—	5.1 mo	6	R 7 491 PFS proxy	7
Glasdegib and LoDAC Variant #01 Partial	—	R 892	28d	—	8.3 mo	2	R 1 784 PFS proxy	1
Clofarabine and LoDAC Variant #01 Partial	—	R 892	49d	—	—	~1	~R 892 indirect	—
CPX-351 monotherapy Variant #01 Partial	—	—	49d	—	9.3 mo	1	—	1
Clofarabine monotherapy Variant #01 Partial	—	—	42d	—	—	12	—	1
Best supportive care Partial	—	—	—	—	5.8 mo	—	—	5

16 of 16 regimens shown